SBO-154 / Sun Pharma Advanced Research Company - LARVOL DELTA

A phase 1, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors. (ASCO 2026) - P1 | "Cohorts 1 and 2 have been completed without any DLTs, and enrolment in Cohort 3 is ongoing as of December 2025. Clinical Trial Registration Number: NCT07042100."

Clinical • First-in-human • Metastases • P1 data • PK/PD data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • MUC1

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=177 | Recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=177 | Not yet recruiting | Sponsor: Sun Pharma Advanced Research Company Limited

New P1 trial • Solid Tumor

SPARC submits application for its ADC to US FDA to conduct global phase-1 study (Business Standard) - "Sun Pharma Advanced Research Company (SPARC) said that it has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for its antibody-drug conjugate (ADC) SBO-154. The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors."

IND • New P1 trial • Oncology • Solid Tumor